Paris, France, July 18, 2023 – 7:00 a.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow degenerative processes related to aging and improve the functional outcomes of patients suffering from age-related diseases and SEQENS, an integrated global player in solutions and ingredients for the pharmaceutical and specialty markets offering a broad portfolio of active ingredients, pharmaceutical intermediates and specialty products, announce the signing of a framework contract for the production of the active ingredient of Sarconeos (BIO101), its main drug candidate developed for three indications: severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy .
SEQENS will ensure the production of the active ingredient of Sarconeos (BIO101) in France at its plant in Villeneuve La Garenne near Paris. This historic site was modernized and extended in 2020 with the opening of a unit for the production of high-potential active pharmaceutical ingredients (API). The production center is equipped with state-of-the-art infrastructure that respects SEQENS’ commitments in terms of decarbonization and employee health and safety.